An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL) Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01532700
• Other study ID #: PMH-GSK2110183-CLL001
• Status: Completed
• Phase: Phase 2
• Start date: February 2012
• Est. completion date: June 30, 2017

Study information

• Verified date: September 2019
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2, open-label, single institution trial of combination of intravenous (IV) ofatumumab and oral GSK2110183 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). Patients must have received at least one prior line of therapy containing fludarabine (single-agent or combination therapy). During the initial 6 months Treatment Phase, ofatumumab will be administered weekly for 8 doses, then once every 4 week cycle for an additional 4 doses (dose and schedule identical to the pivotal phase 2 trial) and GSK2110183 will be given daily PO (Treatment Phase). There will be an initial 10 day lead-in with GSK2110183 alone prior to initiation of ofatumumab to allow for evaluation of changes in cell surface expression due to GSK2110183 and for GSK2110183 pharmacokinetic studies (Lead-in Phase). The official Cycle 1 Day 1 will start on the date of first dose of ofatumumab. Cycle duration = 4 weeks. Patients will be assessed for safety, disease assessment, response, and survival on day 1 of each cycle during the Treatment Phase. A formal review of safety data by the Data Safety Monitoring Board (DSMB) after the first 6 patients have completed cycle 1 of the Treatment Phase will be performed before continuing accrual. All patients achieving SD, PR or CR by the end of the Treatment Phase will proceed to the Maintenance Phase. Patients with PD at any time, including by the end of Treatment Phase, will be taken off study. During the Maintenance Phase, single-agent GSK2110183 will be administered daily for a maximum of 12 months (12 cycles). Maximum duration on any study drug is 18 months (18 cycles). During the Follow-up Phase, patients will be assessed for safety, disease assessment, response, and survival every 3 months through month 36 (year 3), or until subsequent CLL therapy or death, whichever comes first. Key indications for study withdrawal are progressive disease, intolerable toxicity, or completion of therapy

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: June 30, 2017
• Est. primary completion date: June 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must fulfill all of the following criteria to be eligible for admission to the study:

• A confirmed diagnosis of B-cell CLL by IWCLL 2008 criteria (Appendix 1)

• Patients must have evidence of disease progression as evidenced by rapid doubling of peripheral lymphocyte count, progressive lymphadenopathy or hepatosplenomegaly, worsening anemia or thrombocytopenia, or progressive constitutional symptoms [including fatigue, weight loss, night sweats, fever (without infection)]

• Must be relapsed or refractory to at least one prior fludarabine-containing regimen (no maximum number of prior regimens).

• Age > 18 years.

• ECOG performance status of 0, 1 or 2 (Appendix 3)

• Signed the Informed Consent form

• Life expectancy of = 6 months

• Able to swallow and retain oral medication

• Normal HbA1C = 0.07

• Fasting blood sugar < 7mmol/L

Exclusion Criteria:

• Subjects meeting any of the following criteria are excluded from this study:

• CLL therapy, including stem cell transplantation, within 4 weeks of study initiation. Corticosteroids alone may be administered up to seven days prior to the first dose of study drug.

• Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to enrollment, whichever is longer, or currently participating in any other interventional clinical study

• Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy

• Known hypersensitivity to ofatumumab, GSK2110183, or any components therein.

• Anticoagulants are permitted only if the subject meets PTT and INR entry criteria (INR and PTT = 1.5 times upper normal limit). Their use must be monitored in accordance with local institutional practice.

• Current use of any anti-platelet agent (e.g. dipyridamole, clopidogrel) other than aspirin (81mg daily).

• Current use of a prohibited medication based on potential drug-drug interaction - a complete list is found in Appendix 1

• Known CNS involvement with CLL

• Transformation to aggressive B-cell malignancy (e.g. large B-cell lymphoma, Richter's syndrome, prolymphocytic leukemia [PLL])

• "Active" autoimmune disease - prior history of autoimmune hemolysis (DAT positive or negative) or immune thrombocytopenia without current active autoimmune disease is allowed

• Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable non-hepatitis B or C chronic liver disease per investigator assessment - please see below for Hepatitis B and C criteria)

• Previously diagnosed diabetes mellitus (Type 1 or 2)

• Other past or current malignancy. Subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible.

• Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, and tuberculosis.

• Any medical condition that would require long-term use (> 1 month) of systemic corticosteroids during study treatment (excludes topical or inhaled corticosteroid use)

• History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae

• QTc = 470 msec on screening ECG

• Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to study entry, congestive heart failure (NYHA III-IV), and arrhythmia unless controlled by therapy, with the exception of extra systoles or minor conduction abnormalities.

• Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease which in the opinion of the investigator may represent a risk for the patient.

• Any major surgery within the prior 4 weeks.

• Known HIV positive

• Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded.

• Positive serology for hepatitis C (HC) defined as a positive test for HCAb, in which case reflexively perform a HC RIBA immunoblot assay on the same sample to confirm the result

• Screening laboratory values: platelets = 30 x 109/L,neutrophils = 0.7 x 109/L,creatinine = 2.0 times upper normal limit, total bilirubin = 1.5 times upper normal limit (unless due to a known history of Gilbert's disease), ALT = 2.5 times upper normal limit, alkaline phosphatase = 2.5 times upper normal limit, INR and PTT = 1.5 times upper normal limit

• Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test at screening.

• Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from study start to one year after the last dose of protocol therapy. Adequate contraception is defined as intrauterine device, double barrier method or total abstinence. Oral contraceptives are not adequate due to potential drug-drug interaction.

• Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy.

Related Conditions & MeSH terms

• Chronic Lymphocytic Leukemia (CLL)
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Drug:
• Ofatumumab with GSK2110183
GSK2110183 125mg OD continuously Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses

Locations

Country	Name	City	State
Canada	University Health Network-Princess Margaret Hospital	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University Health Network, Toronto	Novartis

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate, as Per the IWCLL 2008 Response Criteria	IWCLL Response Criteria 2008-Hallek. Complete response (CR): requires peripheral blood lymphocytes < 4 x 109/L, absence of significant lymphadenopathy (>1.5cm), no organomegaly, normal CBC, bone marrow must be at least normocellular; Complete Remission with incomplete bone marrow recovery (CRi): fulfill all the criteria for CR but have persistent anemia, thrombocytopenia or neutropenia apparently unrelated to disease activity but related to drug toxicity; Partial Remission (PR): = 50% decrease in the peripheral blood lymphocytes from baseline, > 50% reduction in the sum products of up to 6 lymph nodes, > 50% reduction in hepatomegaly and/or neutrophils > 1.5 x109/L, platelets > 100 x109/L, hemoglobin > 110 g/L; Stable Disease: Not CR, PR or PD (equivalent to nonresponse); Progressive Disease: Lymphadenopathy, or appearance of any new lesion/organomegaly, > 50% increase in the size of the liver and/or spleen, > 50% increase in the absolute number of circulating lymphocytes	36 months
Secondary	Stable Disease, Response Rate, Toxicity (as Graded Per NCI CTC Version 4.03)		36 months
Secondary	Median Progression Free Survival, Overall Survival	Progression Free Survival (PFS) is defined as the length of time between the date of first dose of study treatment (GSK2110183) and the earliest date of disease progression or death due to any cause.; Overall survival is defined as the length of time between the date of first dose of study treatment (GSK2110183) and death due to any cause.	36 months
Secondary	Median Duration of Response	Duration of Response (DOR) is defined, for the subset of patients with a CR or PR, as the time from first documented evidence of CR or PR until first documented disease progression or death due to any cause. Duration of response will be summarized descriptively using Kaplan-Meier medians and quartiles.	36 months